Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates

Core Viewpoint - Penumbra (PEN) reported quarterly earnings of $1.18 per share, exceeding the Zacks Consensus Estimate of $1.12 per share, and showing an increase from $0.97 per share a year ago, representing an earnings surprise of +5.36% [1] Financial Performance - The company achieved revenues of $385.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.74%, and up from $315.52 million year-over-year [2] - Over the last four quarters, Penumbra has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Penumbra shares have increased approximately 9.2% since the beginning of the year, compared to a 0.7% gain in the S&P 500 [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, with current consensus EPS estimates at $1.12 for the upcoming quarter and $5.06 for the current fiscal year [7] - The Zacks Rank for Penumbra is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Penumbra belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8]